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Results.— One hundred and seventy-three paired measurements
were compared. The mean CO (SD) was 2.5(1.4) l/min with TEE-
CO and 2.3(1.4) l/min with PRAM-CO. The mean bias was 0.2 l/min
with agreements limits —2.4 and 2.8 l/min. Pearson’s correlation
was 0.29 giving a percentage error of 108%. In the group with median
BSA < 1.10 m2 (n = 26, 131 measures), mean CO was 1.9 (0.7) l/min
with TEE-CO and 1.8(0.6) l/min with PRAM-CO. The mean bias was
0.03 l/min with agreements limits —1.06 and 1.13 l/min. Pearson’s
correlation was 0.64 giving a percentage error of 60%.
Conclusions.— Differences between PRAM and TEE were signiﬁcant
at all ages and BSA. These results do not support the use of the
Mostcare® monitor to evaluate CO in the setting of pediatric cardiac
surgery.
http://dx.doi.org/10.1016/j.acvd.2013.06.039
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Introduction.— Heart transplantation is the gold standard therapy
for pediatric end-stage heart failure. Sometimes, the waiting time
for a transplant may be long and a mechanical support is required
despite the use of conventional inotropic drugs. Levosimendan was
proved to be safe and efﬁcient for the treatment of postoperative
low cardiac output syndrome in children.
Aims.— To evaluate the effects of levosimendan in children who are
waiting for heart transplantation.
Patients and methods.— In this single-center retrospective study,
all the pediatric patients (under 18 years) in end-stage heart fail-
ure and with criteria for mechanical support, were included. All
the patients were on the waiting list for heart transplantation. Each
patient received at least one 24-hour infusion of levosimendan until
either heart transplantation or mechanical support initiation. Clini-
cal, biological and echocardiographic data were analyzed according
to the infusions of levosimendan.
Results.— A total of six patients were included over a period of
24 months. The median age was 2 years (2 months—15 years). A
total of 82 infusions were performed. Levosimendan had a positive
effect on enteral feeding. The median BNP level decreased signif-
icantly between day 0 and day 2 (2443 ng/L [1458—3819] versus
1358 ng/L [1025—2534], P = 0.003). While only a trend was noted in
the improvement of the left ventricular ejection fraction (P = 0.054
by the Simpson’s method and P = 0.068 by the Teicholz method), the
subaortic velocity time integral was signiﬁcantly improved between
day 0 and day 8 (12.8 cm/s [10—14.5] versus 15.3 cm/s [14.3—16.9],
P = 0.041). Even if the efﬁcacy of levosimendan seemed to pro-
gressively decrease over the time, the use of this drug allowed an
average lifetime without mechanical support of 177 days. During
this study, no adverse events have been reported, or attributed, to
the use of levosimendan.
Conclusion.— Levosimendan improves hemodynamics in children
in end-stage heart failure, allowing several months of life with-
out mechanical support. This study argues for a systematic use
of levosimendan, in addition to the usual inotropic drugs, in this
context. Levels of BNP, quality of enteral feeding and echocar-
diographic parameters may help to determine the best timing for
infusions.
http://dx.doi.org/10.1016/j.acvd.2013.06.040
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Introduction.— Rejection following cardiac transplant remains
an important cause of morbidity and mortality as well as the
complications of the immunosuppressive therapy. Thus, surveil-
lance of paediatric heart transplant patients is crucial to prevent
these risks or, at least, to allow an early treatment. However, only
few international guidelines have been established concerning the
modalities of this monitoring.
Aims.— To collect and to compare the different practices of paedi-
atric heart transplant surveillance in France.
Patients and methods.— It was a descriptive multicenter study. Each
French paediatric cardiologic centres was contacted by e-mail to
complete an electronic questionnaire.
Results.— Eight centres were involved in the surveillance (includ-
ing seven centres performing paediatric heart transplantation) of
these patients. The average number of followed patients was 16.1
(2—50) per centre. The average number of involved physicians was
3.7 (1—8) including 38% of paediatric cardiologists. Only two cen-
tres had a devoted nurse for this activity. Echocardiography was
considered to be reliable for the early detection of transplant
rejection by 57% of centres. Isovolumic relaxation time was always
collected. Whereas TM measurements were frequently analyzed,
other Doppler measurements were inconsistently reported. Myocar-
dial strain analysis (using speckle tracking method) was almost never
performed (14%). Coronarography was systematically performed in
43%, coronary CT angiogram in 28% and cardiac MRI in 14%. For
patients aged above 1 year, cardiac biopsies were systematically
performed in 86%. The prevention of the transplant coronary artery
disease was conducted using pravastatin in 86%, aspirin in 28% and
clopidogrel in 14%.
Conclusion.— The French practices for the monitoring of paediatric
heart transplant patients are heterogeneous due to the absence of
national guidelines. This study highlights the need for a national
register to establish consensuses for the management of these
patients.
http://dx.doi.org/10.1016/j.acvd.2013.06.041
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